SCHEMBL4613610

SCHEMBL4613610

Cc1c(-c2ccnc(Nc3ccc(N(C)C)c([N+](=O)[O-])c3)n2)c(C)n(C)c1C#N

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 15/20 0.58
CDK4 P11802 13/20 0.58
PLK1 P53350 1/20 0.36
IKBKB O14920 1/20 0.36
ALDH1A1 P00352 1/20 0.36
ABL1 P00519 3/20 0.36
BCR P11274 2/20 0.36
PRKCA P17252 2/20 0.36
AURKA O14965 1/20 0.35
CCNT1 O60563 1/20 0.35
CCNB2 O95067 1/20 0.35
CCNE2 O96020 1/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35
CCNA2 P20248 1/20 0.35
CCND1 P24385 1/20 0.35
CCNE1 P24864 1/20 0.35
ABL2 P42684 1/20 0.35
GSK3B P49841 1/20 0.35
CDK7 P50613 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4614032 0.82 CDK2 (0.80) CDK2CDK4
SCHEMBL4613643 0.80 CDK2 (0.50) CDK2CDK4PLK1IKBKBABL1
SCHEMBL2087002 0.79 CDK2 (0.72) CDK2CDK4PLK1IKBKBALDH1A1
SCHEMBL4615045 0.78 CDK2 (0.68) CDK2CDK4
SCHEMBL6605375 0.77 CDK2 (0.62) CDK2CDK4PLK1IKBKBALDH1A1
SCHEMBL6279175 0.74 CDK2 (0.61) CDK2CDK4IKBKBALDH1A1ABL1
SCHEMBL29369233 0.73 CDK2 (1.00) CDK2CDK4PLK1ABL1AURKA
SCHEMBL4798545 0.73 CDK2 (1.00) CDK2CDK4PLK1ABL1AURKA
SCHEMBL27664535 0.73 CDK2 (0.59) CDK2CDK4PLK1IKBKBALDH1A1
SCHEMBL2086429 0.73 CDK2 (0.69) CDK2CDK4PLK1IKBKBABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100425239-C Therapeutic applications of 2-substituted 4-heteroarylpyrimidines CYCLACEL LTD (GB) 2008-10-15 CN claimed
EP-1572211-B1 THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES CYCLACEL LTD (GB) 2008-02-20 EP claimed
CN-1720049-A Therapeutic applications of 2-substituted 4-heteroarylpyrimidines CYCLACEL LTD (GB) 2006-01-11 CN claimed
US-20050282843-A1 Therapeutic applications of 2-substituted 4-heteroarylpyrimidines CYCLACEL LIMITED (GB) 2005-12-22 US claimed
EP-1572211-A1 THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES Cyclacel Limited (GB) 2005-09-14 EP claimed
WO-2004056368-A1 THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLRYRIMIDINES CYCLACEL LIMITED (GB) 2004-07-08 WO claimed
CN-100425239-C Therapeutic applications of 2-substituted 4-heteroarylpyrimidines CYCLACEL LTD (GB) 2008-10-15 CN disclosed
EP-1572211-B1 THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES CYCLACEL LTD (GB) 2008-02-20 EP disclosed
EP-1572211-B1 THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES CYCLACEL LTD (GB) 2008-02-20 EP disclosed
CN-1720049-A Therapeutic applications of 2-substituted 4-heteroarylpyrimidines CYCLACEL LTD (GB) 2006-01-11 CN disclosed
US-20050282843-A1 Therapeutic applications of 2-substituted 4-heteroarylpyrimidines CYCLACEL LIMITED (GB) 2005-12-22 US disclosed
EP-1572211-A1 THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES Cyclacel Limited (GB) 2005-09-14 EP disclosed
WO-2004056368-A1 THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLRYRIMIDINES CYCLACEL LIMITED (GB) 2004-07-08 WO disclosed
WO-2004056368-A1 THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLRYRIMIDINES CYCLACEL LIMITED (GB) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282843-A1 Therapeutic applications of 2-substituted 4-heteroarylpyrimidines HRH2, HRH3, CYTH3 CDK2 810/4885CDK4 1254/4885PLK1 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.